AcuCort AB (”AcuCort” eller ”Bolaget”) har presenterat en Q2-rapport där mycket kretsar kring den st...
CoinShares International (CS) redovisade en stark justerad EBITDA under Q2 24 på 26,6 miljoner pund ...
Redeye provides a more in-depth review of AcouSort’s Q2 report, which did not include any major surp...
STENOCARE A/S (“STENOCARE” or the “Company”) has executed on several strategically important milesto...
Supported by the latest troponin data generated from whole blood samples on the final commercial car...
Redeye comments on Maximum Entertainment’s Q2-results which saw softer topline than expected while a...
Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mecha...
We cut '24e-'26e EBITDA by 17-9% Still expect meaningful share of hardware-related sales NTM EV/EBIT...
Redeye estimates an 85% probability of the Neonode side settling against Samsung in mid-2025, which ...
Redeye views favorably the announcement of the first order from the US Department of Veterans Affair...
Kvällen den 27 augusti offentliggjorde edyoutec sin delårsrapport för kv2 2024.
Redeye returns with an update following Alzecure's Q2 report and recent activities in the company.
Q2 EBITDA 1% below cons on Sportsbook and Platform miss Decent start to Q3 with Media sales up 37% y...
Redeye comments on GiG’s Q2 results, which were overall close to our forecast although Media was str...
Active Biotechs samarbete i USA kring tasquinimod har påbörjat rekrytering till en fas 2-studie inom...
